Use of Vasa swaras bhavit vardhaman Pippali in patients of Tamak Shwas

Phase 2/3

Not yet recruiting

• Conditions: Mild persistent asthma. Ayurveda Condition: TAMAKASVASAH,

• Registration Number: CTRI/2025/05/086850
• Lead Sponsor: Government Akhandanand Ayurved College

Brief Summary

According to Ayurveda Shwasaroga is a chronic disease of Pranavahastrotas. In Ayurveda “Prana” word refers to ‘Prana Vayu’(oxygen) or ‘Life’. Acharya Charak has described 5 types of Shwasa roga, Tamaka Shwasa is one of them. As per Acharya Charaka the roots of PranavahaSrotas are located in Hridaya & Mahasrotasa. Tamaka Shwasa is caused by vitiated Vata and Kapha mainly and designated as PittasthanaSamudhbhavaVydahi. The classical features of Tamaka Shwasa are Shwasakruchcchata, Ghurghurkama, Kasa, Asamyaka nidra, Asinolabhate saukhyama etc. Tamak Shwasa comprises mainly two Avasthas ,Vegkalin(Status Asthmaticus) and Vegottarkalin Avastha (Post Paroxysmal Condition). Both this Avashtha has different treatment modalities. In Vegkalin avastha ,Doshghna And Vatanulomak treatment is given while in Vegottarkalin Avastha, Deepan, Pachan, Shodhan/Strotoprasadan, Anuloman and Rasayan Chikitsa is taken into consideration.

Tamaka Shwas is Pittasthansamudbhav vyadhi. It is caused by vitiated Vata and Kaph doshamainly. Due to vitiated doshas there is agni dushti , ama and strotoavrodhjanya symptoms.Ayurveda has complete approach to root eradication of disease i.e.moolvyadhi nirakaranthrough Apunarbhav Chikitsa.Therefore Ayurvedic management of Tamak Shwas is done insuch a way that it works on root cause of the vyadhi i.e it improves status of agni ,reducesama, treat strotoavrodh and provide strength not only to Pranavah strotas but whole bodyby Rasayan proparties.

As per ayurvedic classics,therapeutic principle of Vegottarkalin Shwas Roga,the food anddrugs having kapha vatashamak, Vatanulomak, strotoshodhak properties are useful intreatment of Tamak Shwasa.Pippali Vardhaman Rasayan instructed in Rasayanv Pad 3 has been specially indicated forShwas Kas Roga. Pippali has viDeepan ,Rasayan, Katu, Laghu, Vatshleshmahar AndStrotoshodhak, Yogavahi properties. Its active ingredients like viiPiperine, Periongumine,Dihydro Stigmasterol promote respiratory health. So by this ingredient action, Pippali actsas decongestant, bronchodilator and expectorant. Vasa is also viiikaphanashak and swashar.It is an important drug acting on Pranavah Strotas, specifically as expectorant andbronchodialator. Its active ingredient Bromhexine has mucolytic property. So it is plannedand assumed that Pippali if processed in Vasa Swaras , then the efficacy of Pippali Rasayancould be higher and the Ushna Tikshna Guna of Pippali could neutralized in Vasa processing,as Vasa is Sheet Veerya drug.

Detailed Description

Not available

Study Timeline

• Last Update Posted: 2025-05-13
• Study Start: 2025-05-25

Recruitment & Eligibility

• Status: Not Yet Recruiting
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• Both male & female Patients having age greater than or equal to 18years and less than or equal to 60 years of age Patient with chronicity of Tamaka Shwasa Less than 5 years.
• Patients with classical signs and symptoms of Tamaka Shwasa described in ancient Ayurveda text will be selected for present study such as ShwasaKrichchhata (Dyspnoea) Ghurghurukama (Wheezing sound) Kasa (Cough) Asamyakanidra (Disturbedsleep) Kantodhwamsa (Hoarseness of voice) Pinasa (Coryza) ShleshmaVimokshanteMuhurtam Sukham (After expectoration patient feels better).
• ParshvaAvgrihyate (Chest tightness) Aasinolabhatesaukhyama (Comfortable in sitting position) Meghambusheetpragvataihi abhivardhate(increase symptoms after weather change) 4.PEF greater than or equal to 50 %.

Exclusion Criteria

• Acute Dyspnoea, Relative Hypoxia And Cyanosis (Status Asthmaticus).
• Patients suffering from any systemic or chronic illness like Emphysema, Type 2diabetes mellitus, Hypertension, Renal diseases and Cardiac diseases.
• Patients of Cor pulmonale, Pulmonary Hypertension, Cardiac Asthma and with severe exacerbation.
• Any acute systemic disease or Infection, post long covid lung disease/complication.
• Pregnant and lactating mothers.
• Any malignancy.
• Acute & serious conditions require immediate intervention will be excluded.
• PEF less than 50% ILD (Interstitial Lung Disease) Pulmonary Fibrosis and Consolidation Chronicity More Than 5 Year.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Results will be assessed on the basis of	7 days | 14 days | 21 days | 30 days | 40 days
gradation of clinical features of Tamaka Shwasa	7 days | 14 days | 21 days | 30 days | 40 days

Secondary Outcome Measures

Name	Time	Method
Peak flow meter reading to access improvement	of lung functions

Trial Locations

Locations (1)

Government Akhandanand Ayurved College and Hospital; 🇮🇳 Ahmadabad, GUJARAT, India

Government Akhandanand Ayurved College and Hospital

🇮🇳Ahmadabad, GUJARAT, India

Mansi Patil

Principal investigator

09834646056

mansipatil50094@gmail.com